Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cyclopropanecarboxylic Acid Amide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 known ✓ | P35228 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropanecarboxylic Acid Amide SCHEMBL8743189 | 0.88 | SMN1; SMN2 (0.46) | SMN1; SMN2GAAKDM4EMAPTKMT2A | |
| SCHEMBL383436 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAKDM4EMAPTKMT2A | |
| SCHEMBL13332956 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAKDM4EMAPTKMT2A | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL6927157 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAKDM4EMAPTKMT2A | |
| SCHEMBL9797557 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAKDM4EMAPTKMT2A | |
| SCHEMBL28418543 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAKDM4EMAPTKMT2A | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL5661 | 0.87 | — | — | |
| SCHEMBL12513456 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2GAAKDM4EMAPTKMT2A | |
| SCHEMBL12437076 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2GAAKDM4EMAPTKMT2A | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL29183025 | 0.85 | KDM4E (0.46) | SMN1; SMN2GAAKDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406447-A | The crystal form of pyrrolopyridine compounds | 基因泰克公司 | 2017-11-28 | — | — | CN | disclosed |
| WO-2010011584-A2 | PROCESS FOR MAKING A RENIN INHIBITOR | MERCK & CO., INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |